Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis

BACKGROUND: The combination of sofosbuvir and daclatasvir has a well-established safety profile and improves clinical outcomes in HCV patients. In silico and in vitro studies suggest that sofosbuvir/daclatasvir may show antiviral activity against SARS-CoV-2. METHODS: Three clinical trials comparing...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Antimicrob Chemother
Main Authors: Simmons, Bryony, Wentzel, Hannah, Mobarak, Sara, Eslami, Gholamali, Sadeghi, Anahita, Ali Asgari, Ali, Abbaspour Kasgari, Hamideh, Tirgar Fakheri, Hafez, Merat, Shahin, Hill, Andrew
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Systematic Review
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7665526/
https://ncbi.nlm.nih.gov/pubmed/33063117
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jac/dkaa418
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados